Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2017

01-06-2017

The influence of platelet membranes on tumour cell behaviour

Authors: LA Coupland, EJ Hindmarsh, EE Gardiner, CR Parish

Published in: Cancer and Metastasis Reviews | Issue 2/2017

Login to get access

Abstract

The significant role of platelets in the protection of tumour cells from immune attack and shear forces and the promotion of tumour cell extravasation from the bloodstream in the process of haematogenous metastasis have been extensively studied. The role of platelets, and in particular platelet membranes, in the promotion of a more metastatic phenotype in tumour cells is a more recent and, therefore, less well-recognised area of research. This review article summarises studies that have focused on the impact of tumour cell interactions with platelets and platelet membranes on tumour cell behaviour in vitro and in vivo. Furthermore, the gene expression changes that occur within tumour cells following contact with platelet membranes are also extensively reviewed. Overall, the interaction of platelet membranes with tumour cells results in a more invasive phenotype and the promotion of epithelial to mesenchymal transition with our own genetic studies revealing that matrix metalloproteinase-1, plasminogen activator inhibitor-1 and interleukin-8 are globally upregulated in a range of tumour cell lines.
Literature
1.
Liotta, L. A. (1992). Cancer cell invasion and metastasis. Scientific American, 266(2), 54–59 62–53.CrossRefPubMed
2.
Nierodzik, M. L., Klepfish, A., & Karpatkin, S. (1995). Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thrombosis and Haemostasis, 74(1), 282–290.PubMed
3.
Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews. Cancer, 11(2), 123–134.CrossRefPubMed
4.
5.
6.
Meikle, C. K., Kelly, C. A., Garg, P., Wuescher, L. M., Ali, R. A., & Worth, R. G. (2016). Cancer and thrombosis: the platelet perspective. Frontiers in Cell and Development Biology, 4, 147. doi:10.​3389/​fcell.​2016.​00147.
7.
8.
Baj-Krzyworzeka, M., Majka, M., Pratico, D., Ratajczak, J., Vilaire, G., Kijowski, J., et al. (2002). Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Experimental Hematology, 30(5), 450–459.CrossRefPubMed
9.
Janowska-Wieczorek, A., Marquez-Curtis, L. A., Wysoczynski, M., & Ratajczak, M. Z. (2006). Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion, 46(7), 1199–1209.CrossRefPubMed
10.
Dashevsky, O., Varon, D., & Brill, A. (2009). Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. International Journal of Cancer, 124(8), 1773–1777. doi:10.​1002/​ijc.​24016.CrossRefPubMed
11.
Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576–590.CrossRefPubMedPubMedCentral
12.
13.
Orellana, R., Kato, S., Erices, R., Bravo, M. L., Gonzalez, P., Oliva, B., et al. (2015). Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer, 15, 290. doi:10.​1186/​s12885-015-1304-z.CrossRefPubMedPubMedCentral
14.
Pang, J. H., Coupland, L. A., Freeman, C., Chong, B. H., & Parish, C. R. (2015). Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process. Clinical & Experimental Metastasis, 32(5), 495–505. doi:10.​1007/​s10585-015-9722-5.CrossRef
15.
Dovizio, M., Alberti, S., Sacco, A., Guillem-Llobat, P., Schiavone, S., Maier, T. J., et al. (2015). Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. Biochemical Society Transactions, 43(4), 707–714. doi:10.​1042/​BST20140322.CrossRefPubMedPubMedCentral
16.
Gasic, G. J., Gasic, T. B., & Stewart, C. C. (1968). Antimetastatic effects associated with platelet reduction. Proceedings of the National Academy of Sciences of the United States of America, 61(1), 46–52.CrossRefPubMedPubMedCentral
17.
Karpatkin, S., & Pearlstein, E. (1981). Role of platelets in tumor cell metastasis. [Review]. Annals of Internal Medicine, 95(5), 636–641.CrossRefPubMed
18.
Kim, Y. J., Borsig, L., Varki, N. M., & Varki, A. (1998). P-selectin deficiency attenuates tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 95(16), 9325–9330.CrossRefPubMedPubMedCentral
19.
Amirkhosravi, A., Amaya, M., Siddiqui, F., Biggerstaff, J. P., Meyer, T. V., & Francis, J. L. (1999). Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets, 10(5), 285–292. doi:10.​1080/​09537109975915.CrossRefPubMed
20.
Nieswandt, B., Hafner, M., Echtenacher, B., & Mannel, D. N. (1999). Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Research, 59(6), 1295–1300.PubMed
21.
Jain, S., Zuka, M., Liu, J., Russell, S., Dent, J., Guerrero, J. A., et al. (2007). Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proceedings of the National Academy of Sciences of the United States of America, 104(21), 9024–9028.CrossRefPubMedPubMedCentral
22.
Kato, Y., Kaneko, M. K., Kunita, A., Ito, H., Kameyama, A., Ogasawara, S., et al. (2008). Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Science, 99(1), 54–61. doi:10.​1111/​j.​1349-7006.​2007.​00634.​x.PubMed
23.
Jain, S., Russell, S., & Ware, J. (2009). Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. Journal of Thrombosis and Haemostasis, 7(10), 1713–1717.CrossRefPubMed
24.
Coupland, L. A., Chong, B. H., & Parish, C. R. (2012). Platelets and P-Selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Research, 72(18), 4662–4671.
25.
Lonsdorf, A. S., Kramer, B. F., Fahrleitner, M., Schonberger, T., Gnerlich, S., Ring, S., et al. (2012). Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. The Journal of Biological Chemistry, 287(3), 2168–2178.CrossRefPubMed
26.
Chang, Y. S., di Tomaso, E., McDonald, D. M., Jones, R., Jain, R. K., & Munn, L. L. (2000). Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proceedings of the National Academy of Sciences of the United States of America, 97(26), 14608–14613.CrossRefPubMedPubMedCentral
27.
Janowska-Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez-Curtis, L., Machalinski, B., Ratajczak, J., et al. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113(5), 752–760.CrossRefPubMed
28.
Park, H. B., Yang, J. H., & Chung, K. H. (2011). Characterization of the cytokine profile of platelet rich plasma (PRP) and PRP-induced cell proliferation and migration: upregulation of matrix metalloproteinase-1 and -9 in HaCaT cells. Korean Journal of Hematology, 46(4), 265–273. doi:10.​5045/​kjh.​2011.​46.​4.​265.CrossRefPubMedPubMedCentral
29.
30.
31.
Dovizio, M., Maier, T. J., Alberti, S., Di Francesco, L., Marcantoni, E., Munch, G., et al. (2013). Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Molecular Pharmacology, 84(1), 25–40. doi:10.​1124/​mol.​113.​084988.CrossRefPubMed
32.
Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M. K., Mishima, K., Yatomi, Y., et al. (2007). Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. The Journal of Biological Chemistry, 282(36), 25993–26001.CrossRefPubMed
33.
Martin-Villar, E., Megias, D., Castel, S., Yurrita, M. M., Vilaro, S., & Quintanilla, M. (2006). Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. Journal of Cell Science, 119(Pt 21), 4541–4553. doi:10.​1242/​jcs.​03218.CrossRefPubMed
34.
35.
36.
37.
Yu, L. X., Yan, L., Yang, W., Wu, F. Q., Ling, Y., Chen, S. Z., et al. (2014). Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nature Communications, 5, 5256. doi:10.​1038/​ncomms6256.CrossRefPubMed
38.
Zhang, G., Han, J., Welch, E. J., Ye, R. D., Voyno-Yasenetskaya, T. A., Malik, A. B., et al. (2009). Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. Journal of Immunology, 182(12), 7997–8004. doi:10.​4049/​jimmunol.​0802884.CrossRef
39.
40.
Tadokoro, S., Shattil, S. J., Eto, K., Tai, V., Liddington, R. C., de Pereda, J. M., et al. (2003). Talin binding to integrin beta tails: a final common step in integrin activation. Science, 302(5642), 103–106. doi:10.​1126/​science.​1086652.CrossRefPubMed
41.
Nieswandt, B., Moser, M., Pleines, I., Varga-Szabo, D., Monkley, S., Critchley, D., et al. (2007). Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. The Journal of Experimental Medicine, 204(13), 3113–3118. doi:10.​1084/​jem.​20071827.CrossRefPubMedPubMedCentral
42.
Petrich, B. G., Marchese, P., Ruggeri, Z. M., Spiess, S., Weichert, R. A., Ye, F., et al. (2007). Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. The Journal of Experimental Medicine, 204(13), 3103–3111. doi:10.​1084/​jem.​20071800.CrossRefPubMedPubMedCentral
43.
44.
Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., et al. (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. The Journal of Clinical Investigation, 114(12), 1714–1725.CrossRefPubMedPubMedCentral
45.
46.
Mannori, G., Crottet, P., Cecconi, O., Hanasaki, K., Aruffo, A., Nelson, R. M., et al. (1995). Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Research, 55(19), 4425–4431.PubMed
47.
48.
49.
50.
51.
Sunami, E., Tsuno, N., Osada, T., Saito, S., Kitayama, J., Tomozawa, S., et al. (2000). MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. The Oncologist, 5(2), 108–114.CrossRefPubMed
52.
53.
54.
Andreasen, P. A. (2007). PAI-1—a potential therapeutic target in cancer. Current Drug Targets, 8(9), 1030–1041.CrossRefPubMed
55.
56.
David, J. M., Dominguez, C., Hamilton, D. H., & Palena, C. (2016). The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines, 4(3), 22–37.
57.
58.
59.
60.
61.
62.
Holting, T., Siperstein, A. E., Clark, O. H., & Duh, Q. Y. (1995). Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. European Journal of Endocrinology, 132(2), 229–235.CrossRefPubMed
63.
64.
65.
Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., et al. (2006). The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Reviews, 25(3), 387–408. doi:10.​1007/​s10555-006-9004-4.CrossRefPubMed
66.
67.
Gouveia-Fernandes, S., Carvalho, T., Domingues, G., Bordeira-Carrico, R., Dias, S., & Serpa, J. (2016). Colorectal cancer aggressiveness is related to fibronectin over expression, driving the activation of SDF-1:CXCR4 axis. International Journal of Cancer and Clinical Research, 3(8), 72–81.
68.
Yan, T., Lin, Z., Jiang, J., Lu, S., Chen, M., Que, H., et al. (2015). MMP14 regulates cell migration and invasion through epithelial-mesenchymal transition in nasopharyngeal carcinoma. American Journal of Translational Research, 7(5), 950–958.PubMedPubMedCentral
69.
Duggan, C., Kennedy, S., Kramer, M. D., Barnes, C., Elvin, P., McDermott, E., et al. (1997). Plasminogen activator inhibitor type 2 in breast cancer. British Journal of Cancer, 76(5), 622–627.CrossRefPubMedPubMedCentral
70.
Robert, C., Bolon, I., Gazzeri, S., Veyrenc, S., Brambilla, C., & Brambilla, E. (1999). Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clinical Cancer Research, 5(8), 2094–2102.PubMed
71.
Su, C. Y., Liu, Y. P., Yang, C. J., Lin, Y. F., Chiou, J., Chi, L. H., et al. (2015). Plasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancer. PloS One, 10(7), 1–15.
72.
73.
Mao, X., Gauche, C., Coughtrie, M. W., Bui, C., Gulberti, S., Merhi-Soussi, F., et al. (2016). The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer. Oncogene, 35(38), 5043–5055. doi:10.​1038/​onc.​2016.​44.CrossRefPubMed
74.
Chen, Y., Satoh, T., Sasatomi, E., Miyazaki, K., & Tokunaga, O. (2001). Critical role of type IV collagens in the growth of bile duct carcinoma. In vivo and in vitro studies. Pathology, Research and Practice, 197(9), 585–596. doi:10.​1078/​0344-0338-00132.PubMed
75.
76.
77.
78.
Mitrugno, A., Sylman, J. L., Ngo, A. T., Pang, J., Sears, R. C., Williams, C. D., et al. (2017). Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. American Journal of Physiology. Cell Physiology, 312(2), C176–C189. doi:10.​1152/​ajpcell.​00196.​2016.CrossRefPubMed
79.
Savore, C., Zhang, C., Muir, C., Liu, R., Wyrwa, J., Shu, J., et al. (2005). Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clinical & Experimental Metastasis, 22(5), 377–390. doi:10.​1007/​s10585-005-2339-3.CrossRef
80.
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011). Cyclin D as a therapeutic target in cancer. Nature Reviews. Cancer, 11(8), 558–572. doi:10.​1038/​nrc3090.CrossRefPubMed
81.
82.
Song, G., Xu, S., Zhang, H., Wang, Y., Xiao, C., Jiang, T., et al. (2016). TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. Journal of Experimental & Clinical Cancer Research, 35(1), 148. doi:10.​1186/​s13046-016-0427-7.CrossRef
83.
Honn, K. V., Cavanaugh, P., Evens, C., Taylor, J. D., & Sloane, B. F. (1982). Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin. Science, 217(4559), 540–542.CrossRefPubMed
84.
85.
Wang, J. L., Chen, Z. F., Chen, H. M., Wang, M. Y., Kong, X., Wang, Y. C., et al. (2014). Elf3 drives beta-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell Death & Disease, 5, e1263. doi:10.​1038/​cddis.​2014.​206.CrossRef
86.
Gajulapalli, V. N., Samanthapudi, V. S., Pulaganti, M., Khumukcham, S. S., Malisetty, V. L., Guruprasad, L., et al. (2016). A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells. The Biochemical Journal, 473(8), 1047–1061. doi:10.​1042/​BCJ20160019.CrossRefPubMed
87.
Rizzolio, S., & Tamagnone, L. (2007). Semaphorin signals on the road to cancer invasion and metastasis. Cell Adhesion & Migration, 1(2), 62–68.CrossRef
88.
Daniel-Carmi, V., Makovitzki-Avraham, E., Reuven, E. M., Goldstein, I., Zilkha, N., Rotter, V., et al. (2009). The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. International Journal of Cancer, 125(12), 2810–2819. doi:10.​1002/​ijc.​24669.CrossRefPubMed
89.
90.
91.
McIlwain, D. R., Berger, T., & Mak, T. W. (2015). Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology, 7(4), doi:10.1101/cshperspect.a026716.
92.
93.
94.
95.
96.
97.
Xie, Y., Camps, J., Awad, K. S., Wangsa, D., Yang, J., Yoo, N., et al. (2011). Abstract 135: MicroRNA repression of BIRC4/XIAP in lung cancer. Paper presented at the AACR 102nd Annual Meeting, Orlando, FL.
98.
99.
Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M. E., Neve, R. M., et al. (2008). Epithelial mesenchymal transition traits in human breast cancer cell lines. Clinical & Experimental Metastasis, 25(6), 629–642. doi:10.​1007/​s10585-008-9170-6.CrossRef
100.
Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., Andre, F., De Cremoux, P., et al. (2013). Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Research, 73(8), 2418–2427. doi:10.​1158/​0008-5472.​CAN-12-2432.CrossRefPubMed
101.
Nurden, A. T., Nurden, P., Sanchez, M., Andia, I., & Anitua, E. (2008). Platelets and wound healing. Frontiers in Bioscience, 13, 3532–3548.PubMed
Metadata
Title
The influence of platelet membranes on tumour cell behaviour
Authors
LA Coupland
EJ Hindmarsh
EE Gardiner
CR Parish
Publication date
01-06-2017
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9671-3

Other articles of this Issue 2/2017

Cancer and Metastasis Reviews 2/2017 Go to the issue

NON-THEMATIC REVIEW

Cleavage and phosphorylation: important post-translational modifications of galectin-3

OriginalPaper

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

OriginalPaper

Platelet-activating factor podoplanin: from discovery to drug development

ReviewPaper

Platelets, circulating tumor cells, and the circulome

NON-THEMATIC REVIEW

Cytokine-induced senescence for cancer surveillance

ReviewPaper

The potential role of platelets in the consensus molecular subtypes of colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits